𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical trials in children with cancer?The problem of early randomisation

✍ Scribed by Pinkerton, Ross


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
73 KB
Volume
35
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Limitations of the randomized trial for
✍ Charles R. Smart πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

the National Cancer Advisory Board of the National Cancer Institute (NCI), made a statement regarding randomized clinical trials (RCTs) that, although helpful in some circumstances, they were not always possible and that clinical judgment coupled with descriptive and other types of studies were also

Missing quality of life data in cancer c
✍ JΓΌrg Bernhard; David F. Cella; Alan S. Coates; Lesley Fallowfield; Patricia A. G πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 1 views

Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other impor

Why are missing quality of life data a p
✍ Diane L. Fairclough; Harriet F. Peterson; Victor Chang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 1 views

Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from se

Statistical analysis of quality of life
✍ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 255 KB πŸ‘ 1 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud